188 related articles for article (PubMed ID: 32350118)
1. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort.
Mitchell KG; Diao L; Karpinets T; Negrao MV; Tran HT; Parra ER; Corsini EM; Reuben A; Federico L; Bernatchez C; Dejima H; Francisco-Cruz A; Wang J; Antonoff MB; Vaporciyan AA; Swisher SG; Cascone T; Wistuba II; Heymach JV; Gibbons DL; Zhang J; Haymaker CL; Sepesi B
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350118
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
3. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer.
Ilie M; Hofman V; Ortholan C; Bonnetaud C; Coëlle C; Mouroux J; Hofman P
Cancer; 2012 Mar; 118(6):1726-37. PubMed ID: 21953630
[TBL] [Abstract][Full Text] [Related]
4. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer.
Barrera L; Montes-Servín E; Hernandez-Martinez JM; Orozco-Morales M; Montes-Servín E; Michel-Tello D; Morales-Flores RA; Flores-Estrada D; Arrieta O
Cancer Immunol Immunother; 2018 Sep; 67(9):1393-1406. PubMed ID: 29974189
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Combination of Preoperative Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) in Patients with Non-Small Cell Lung Cancer: Based on a Large Cohort Study.
Zhang H; Zhang L; Zhu K; Shi B; Yin Y; Zhu J; Yue D; Zhang B; Wang C
PLoS One; 2015; 10(5):e0126496. PubMed ID: 25950176
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical prognostic phenomenon of plasma T-cell-derived circulating DNA level in advanced non-small cell lung cancer.
Sitthideatphaiboon P; Santisukwongchote S; Khunsri S; Sathitruangsak C; Chantranuwat P; Vinayanuwattikun C; Sriuranpong V
Clin Transl Oncol; 2020 Jul; 22(7):1117-1125. PubMed ID: 31754936
[TBL] [Abstract][Full Text] [Related]
7. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
8. CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients.
Barrera L; Montes-Servín E; Hernandez-Martinez JM; García-Vicente MLÁ; Montes-Servín E; Herrera-Martínez M; Crispín JC; Borbolla-Escoboza JR; Arrieta O
Br J Cancer; 2017 Jul; 117(3):385-397. PubMed ID: 28632731
[TBL] [Abstract][Full Text] [Related]
9. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer.
Kobayashi N; Usui S; Kikuchi S; Goto Y; Sakai M; Onizuka M; Sato Y
Lung Cancer; 2012 Feb; 75(2):223-7. PubMed ID: 21764477
[TBL] [Abstract][Full Text] [Related]
10. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.
Yuan C; Li N; Mao X; Liu Z; Ou W; Wang SY
Thorac Cancer; 2017 Jul; 8(4):350-358. PubMed ID: 28544400
[TBL] [Abstract][Full Text] [Related]
11. Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: A single institutional cohort study.
Lan H; Zhou L; Chi D; Zhou Q; Tang X; Zhu D; Yue J; Liu B
Oncotarget; 2017 May; 8(21):35301-35310. PubMed ID: 27845912
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Complete Blood Cell Count-Derived Inflammatory Biomarkers in Early-Stage Non-Small-Cell Lung Cancer.
Shoji F; Kozuma Y; Toyokawa G; Yamazaki K; Takeo S
Ann Thorac Cardiovasc Surg; 2020 Oct; 26(5):248-255. PubMed ID: 32074540
[TBL] [Abstract][Full Text] [Related]
14. Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer.
Schernberg A; Mezquita L; Boros A; Botticella A; Caramella C; Besse B; Escande A; Planchard D; Le Péchoux C; Deutsch E
PLoS One; 2018; 13(10):e0204490. PubMed ID: 30304046
[TBL] [Abstract][Full Text] [Related]
15. Albumin and Neutrophil Combined Prognostic Grade as a New Prognostic Factor in Non-Small Cell Lung Cancer: Results from a Large Consecutive Cohort.
Sun H; Hu P; Shen H; Dong W; Zhang T; Liu Q; Du J
PLoS One; 2015; 10(12):e0144663. PubMed ID: 26656866
[TBL] [Abstract][Full Text] [Related]
16. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of preoperative circulating CD44⁺ lymphocytes and neutrophils predict poor survival for non-small cell lung cancer patients.
Yang SZ; Ji WH; Mao WM; Ling ZQ
Clin Chim Acta; 2015 Jan; 439():172-7. PubMed ID: 25451952
[TBL] [Abstract][Full Text] [Related]
18. Relation between tumor FDG uptake and hematologic prognostic indicators in stage I lung cancer patients following curative resection.
Jeong E; Hyun SH; Moon SH; Cho YS; Kim BT; Lee KH
Medicine (Baltimore); 2017 Feb; 96(5):e5935. PubMed ID: 28151879
[TBL] [Abstract][Full Text] [Related]
19. Blood immune cell biomarkers in lung cancer.
Riemann D; Cwikowski M; Turzer S; Giese T; Grallert M; Schütte W; Seliger B
Clin Exp Immunol; 2019 Feb; 195(2):179-189. PubMed ID: 30246868
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
